{
  "docId": "019de077-0326-7579-845c-ff13347b3147",
  "docSlug": "a6759fd47798a8f3f6e744ad8917865e",
  "documentTitle": "Exscientia | Investor Presentation Deck | 93 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 93,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-0326-7579-845c-ff13347b3147/9",
  "deckHref": "/decks/019de077-0326-7579-845c-ff13347b3147",
  "deckJsonHref": "/decks/019de077-0326-7579-845c-ff13347b3147.json",
  "deckAnchorHref": "/decks/019de077-0326-7579-845c-ff13347b3147#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.04,
        "w": 0.5,
        "x": 0.076,
        "y": 0.928
      },
      "kind": "disclaimer",
      "text": "Does not include Exscientia-designed programmes that entered clinical trials through DSP collaboration; AML = acute myeloid leukaemia; SCLC = small-cell lung cancer",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1daa5b3f-e1f9-488f-9d39-83e147b4bb3a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.85,
        "x": 0.076,
        "y": 0.25
      },
      "kind": "table",
      "text": "Target, Phase, Target Market, Key Differentiation; CDK7, Phase 1/2, Multiple relapsed/refractory solid tumour indications, Precision designed PK/PD specific for mechanism; Identification of high-grade responders; PKC-theta, Phase 1, Multiple immunology indications, Better selectivity, improvements in whole blood potency and low predicted human dose; LSD1, IND-enabling, AML, SCLC and potential additional indications, Optimised therapeutic index by combining reversibility with short-half life, as well as brain penetration to meet high patient need; MALT1, IND-enabling, Multiple haematology indications, Solved potential dose-limiting toxicity issue present in competitor compounds",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "93239e6a-4af9-4444-807d-11b480e838a0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.48,
        "x": 0.076,
        "y": 0.144
      },
      "kind": "title",
      "text": "Differentiated through design and personalised medicine",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "23d5f449-f4fb-4cea-b28c-27c36a977275",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.45,
        "x": 0.076,
        "y": 0.072
      },
      "kind": "title",
      "text": "Why are our clinical candidates different?",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3516a7c2-d7bd-4efe-a5bd-f74ef5b6766a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 14,
      "from": 8,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "a6f36b90-ddc4-42bd-8193-24170d50944c",
      "evidence": "The deck presents a clear solution and its applications",
      "position": 1,
      "objective": "Understand Exscientia's solution",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}